Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Exenatide

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

AstraZeneca · Phase 3 · Completed · Enrollment 119

NCT02635386

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Exenatide once weekly (EQW )n/rn/rn/rn/r
Dapagliflozin (DAPA)n/rn/rn/rn/r
EQW plus DAPAn/rn/rn/rn/r
Dapagliflozin plus Glucophage (MET ER)n/rn/rn/rn/r
Phentermine /Topiramate (PHEN/ TPM) ERn/rn/rn/rn/r

Not shown

  • Exenatide once weekly (EQW ): endpoint not reported
  • Dapagliflozin (DAPA): endpoint not reported
  • EQW plus DAPA: endpoint not reported
  • Dapagliflozin plus Glucophage (MET ER): endpoint not reported
  • Phentermine /Topiramate (PHEN/ TPM) ER: endpoint not reported